Posted on April 9, 2020 by Sitemaster
A panel of top radiation oncologists in the US and the UK has addressed the question of putting off or shortening various kinds of radiation treatment (RT) for prostate cancer at a time when it is best to maintain distance from institutions that treat patients. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: coronavirus, COVID-19, radiation, therapy | Leave a comment »
Posted on February 7, 2020 by Sitemaster
So your sitemaster has been looking through the full report from the APCCC meeting held in Basel last year — as he promised he would. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: advanced, castration-resistant, consensus, hormone-naive, hormone-sensitive, mCRPC, metastatic, mHSPC, nmCRPC, nmHSPC, non-metastatic | 2 Comments »
Posted on February 3, 2020 by Sitemaster
Last August your sitemaster attended and reported from the third iteration of the Advanced Prostate Cancer Consensus Conference (APCCC), held in Basel, Switzerland (see here, here, and here). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: advanced, APCCC, conference, consensus | Leave a comment »
Posted on February 3, 2020 by Sitemaster
According to a media release issued by Bayer a couple of days ago, the combination of androgen deprivation therapy (ADT) + darolutamide (Nubeqa) extends overall survival “significantly” in men with non-metastatic, castration-resistant prostate cancer (nmCRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, darolutamide, nmCRPC, non-metastatic, overall, survival | 2 Comments »
Posted on December 19, 2019 by Sitemaster
Lu-177-PSMA usually improves survival
We’ve seen in a couple of small trials in Germany and Australia that Lu-177-PSMA seemed to provide better than expected survival. … READ MORE … -p>
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: Lu-177-PSMA, lutetium-177, metastatic, PSMA | 5 Comments »
Posted on December 17, 2019 by Sitemaster
Yesterday the U.S. Food and Drug Administration (FDA) approved the use of enzalutamide (Xtandi) for the treatment of metastatic, hormone-sensitive prostate cancer (mHSPC) — also known as metastatic, castration-rsensitive prostate cancer or mCSPC. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: enzalutamide, hormone-sensitive, HSPC, metastatic, Xtandi | 3 Comments »
Posted on October 1, 2019 by Sitemaster
Although at least three randomized clinical trials have told us that adjuvant radiation after prostatectomy often affords better results than just taking a “wait-and-see” approach, … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: adjuvant, early, port-surgery, radiation, salvage | Leave a comment »
Posted on October 1, 2019 by Sitemaster
From a report presented by Hussain yesterday at the annual meeting of the European Society for Medical Oncology (ESMO) we gained detailed insight into the results of the PROfound trial of olaparib (Lynparza), which had been said to be positive last August. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, gene, Lynparza, mCRPC, metastatic, mutation, olaparib | 3 Comments »
Posted on September 20, 2019 by Sitemaster
Does radical prostatectomy (with or without external beam radiation therapy) improve prostate-cancer specific survival by comparison with primary radiation treatment and androgen deprivation therapy (ADT) among patients initially diagnosed with locally advanced (T3) prostate cancer? … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: radiation, stage, surgery, T3, Treatment, trial | 4 Comments »
Posted on September 20, 2019 by Sitemaster
A new paper in Clinical Genitourinary Cancer has provided us with some more detailed information about risk for metastasis in men with recurrent prostate cancer after first-line surgery. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: doubling, Gleason, metastasis, PSA, risk, score, time | 14 Comments »
Posted on September 19, 2019 by Sitemaster
What celebs say and don’t say about prostate cancer (if they say anything at all) has often been difficult for the average patient to understand — as are some of their apparent treatment decisions (if those are actually mentioned). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: celebrity, spokeperson | 4 Comments »
Posted on September 19, 2019 by Sitemaster
In this week’s New England Journal of Medicine (NEJM), there is an interesting article entitled, “Contingent knowledge and looping effects — a 66-year-old man with PSA-detected prostate cancer and regrets”. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: "looping", context, contingent, data, interpretation, knowledge | 7 Comments »
Posted on September 19, 2019 by Sitemaster
A newly published article in Lancet Oncology has suggested that “taxane–platinum combinations have a clinically beneficial role in advanced prostate cancer”. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: cabazitaxel, carboplatin, castration-resistant, mCRPC, metastatic | 2 Comments »
Posted on September 18, 2019 by Sitemaster
Yesterday (September 17, 2019), the US Food and Drug Administration approved apalutamide (Erleada) for treatment of men with metastatic castration-sensitive prostate cancer (mCSPC) … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: apalutamide, approval, Erleada, mCSPC, mHSPC, US | Leave a comment »
Posted on September 17, 2019 by Sitemaster
Stereotactic ablative body radiation (SABR, or sometimes, SBRT) significantly slowed metastatic progression in men with three or fewer metastases (oligometastatic disease). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ablative, body, oligometastasis, radiation, SABR, SBRT, stereotactic | 5 Comments »
